994 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Courier Capital LLC

Courier Capital LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 994 shares of the biopharmaceutical company’s stock, valued at approximately $957,000.

Other large investors have also recently added to or reduced their stakes in the company. Sierra Summit Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $1,011,000. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $749,000. Public Employees Retirement Association of Colorado boosted its holdings in Regeneron Pharmaceuticals by 16.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after buying an additional 2,220 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after buying an additional 1,221 shares in the last quarter. Finally, Congress Wealth Management LLC DE bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $271,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.0 %

Regeneron Pharmaceuticals stock opened at $1,051.03 on Friday. The company has a market capitalization of $115.81 billion, a P/E ratio of 31.05, a P/E/G ratio of 2.17 and a beta of 0.13. The firm’s fifty day simple moving average is $984.27 and its 200-day simple moving average is $950.40. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $688.52 and a 1-year high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on REGN. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,535 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,437,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.